{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:29:48Z","timestamp":1792416588340,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106974","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:39:23Z","timestamp":1767598763000},"page":"106974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of Bruton\u2019s tyrosine kinase inhibitors compared to Teriflunomide in relapsing multiple sclerosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5754-6472","authenticated-orcid":false,"given":"Milene Vit\u00f3ria Sampaio","family":"Sobral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Michaela","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altair Pereira de Melo","family":"Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales Pardini","family":"Fagundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.106974_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233041","article-title":"A review of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis","volume":"17","author":"Airas","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.106974_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221146836","article-title":"Disease-modifying therapies for relapsing\/active secondary progressive multiple sclerosis - a review of population-specific evidence from randomized clinical trials","volume":"16","author":"Bayas","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.106974_bib0003","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1007\/s00415-021-10455-3","article-title":"Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study","volume":"268","author":"Bucello","year":"2021","journal-title":"J. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2026.106974_bib0004","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","article-title":"Discovery of Evobrutinib: an oral, potent, and highly selective, covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases","volume":"62","author":"Caldwell","year":"2019","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.msard.2026.106974_bib0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2026.106974_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103532","article-title":"Inhibitors of Bruton\u2019s tyrosine kinase as emerging therapeutic strategy in autoimmune diseases","volume":"23","author":"De Bondt","year":"2024","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.msard.2026.106974_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primer."},{"issue":"10","key":"10.1016\/j.msard.2026.106974_bib0008","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40263-022-00951-z","article-title":"Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis: pioneering the path towards treatment of progression?","volume":"36","author":"Geladaris","year":"2022","journal-title":"CNS. Drugs"},{"issue":"4","key":"10.1016\/j.msard.2026.106974_bib0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.msard.2026.106974_bib0010","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.msard.2026.106974_bib0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jclinepi.2021.04.014","article-title":"\u201cCorrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision","volume":"137","author":"Guyatt","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.msard.2026.106974_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211007687","article-title":"Inflammation in multiple sclerosis","volume":"14","author":"Haase","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"oct18 2","key":"10.1016\/j.msard.2026.106974_bib0013","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2026.106974_bib0014","series-title":"Orgs., Cochrane Handbook For Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"3","key":"10.1016\/j.msard.2026.106974_bib0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/cjn.2022.60","article-title":"B-cell-directed therapies: a new era in multiple sclerosis treatment","volume":"50","author":"Kanatas","year":"2023","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"issue":"490","key":"10.1016\/j.msard.2026.106974_bib0016","doi-asserted-by":"crossref","first-page":"eaao5563","DOI":"10.1126\/scitranslmed.aao5563","article-title":"Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects","volume":"11","author":"Klotz","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.msard.2026.106974_bib0017","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106974_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000001269","article-title":"Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations","volume":"37","author":"Kr\u00e4mer","year":"2024","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106974_bib0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1756285612474333","article-title":"Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges","volume":"6","author":"Lehmann-Horn","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"10.1016\/j.msard.2026.106974_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS. Med."},{"issue":"25","key":"10.1016\/j.msard.2026.106974_bib0021","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.msard.2026.106974_bib0022","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.106974_bib0023","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fmolb.2020.00062","article-title":"Teriflunomide does not change dynamics of nadph oxidase activation and neuronal dysfunction during neuroinflammation","volume":"7","author":"Mothes","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.msard.2026.106974_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00602","article-title":"Beyond relapses: how BTK inhibitors are shaping the future of progressive MS treatment","author":"Naydovich","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"14","key":"10.1016\/j.msard.2026.106974_bib0025","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O\u2019Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.msard.2026.106974_bib0026","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2026.106974_bib0027","doi-asserted-by":"crossref","first-page":"480","DOI":"10.5603\/PJNNS.a2022.0068","article-title":"Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis","volume":"56","author":"Piasecka-Stryczy\u0144ska","year":"2022","journal-title":"Neurol. Neurochir. Pol."},{"issue":"6","key":"10.1016\/j.msard.2026.106974_bib0028","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/joim.13215","article-title":"Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis","volume":"289","author":"Piehl","year":"2021","journal-title":"J. Intern. Med."},{"issue":"sep24 5","key":"10.1016\/j.msard.2026.106974_bib0029","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.msard.2026.106974_bib0030","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton\u2019s tyrosine kinase inhibitors (BTKIs): review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.msard.2026.106974_bib0031","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11910-022-01229-z","article-title":"Bruton\u2019s tyrosine kinase inhibition in multiple sclerosis","volume":"22","author":"Schneider","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6","key":"10.1016\/j.msard.2026.106974_bib0032","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/1381612827666210701152934","article-title":"Bruton\u2019s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis","volume":"28","author":"Steinmaurer","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.msard.2026.106974_bib0033","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of the Bruton\u2019s tyrosine kinase (BTK) inhibitor Tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drug. RD"},{"key":"10.1016\/j.msard.2026.106974_bib0034","doi-asserted-by":"crossref","first-page":"i3518","DOI":"10.1136\/bmj.i3518","article-title":"Disease modifying therapies for relapsing multiple sclerosis","author":"Wingerchuk","year":"2016","journal-title":"BMJ"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:57Z","timestamp":1780415697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":34,"alternative-id":["S2211034826000106"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106974","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Bruton\u2019s tyrosine kinase inhibitors compared to Teriflunomide in relapsing multiple sclerosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106974"}}